News | Heart Valve Technology | February 28, 2022

TRIA Transcatheter Biopolymer Heart Valve Shows Promise in Pilot Animal Study

Data Presented at Cardiovascular Research Technologies (CRT) Annual Conference

TRIA valve

Transcatheter TRIA valve


February 28, 2022 - Foldax, Inc. has announced the presentation of results from the first animal study of its transcatheter valve from the TRIA biopolymer heart valve portfolio this past weekend at the Cardiovascular Research Technologies (CRT) annual conference. The transcatheter TRIA valve is the third product being developed by the company, with the company’s aortic surgical and mitral surgical valves currently being studied in humans.

Investigators for the pilot study of four ovine subjects reported “the TRIA TAVR (valve) demonstrated satisfactory deployment, function and good hemodynamic results. There was no pannus, calcification or thrombosis on leaflet surfaces (out to as long as 90 days post-implantation).” Investigators included Steven J. Yakubov, MD, of Riverside Methodist Hospital, and James Wittel and Garrett Johnson with Foldax.

On the basis of this pilot study, Foldax plans to conduct a larger pre-clinical study of its transcatheter valve in 2022 intended to support a first-in-human study.

“Expanding TAVR into young patients requires enhanced hemodynamics and durability with greater life expectancy. In this small animal study, we found that the TRIA transcatheter biopolymer valve showed promising hemodynamic results with encouraging durability,” said Yakubov. “Having a TAVR that can last the lifetime of a younger patient is something we need in cardiovascular medicine and it will be exciting to see outcomes from this valve as it moves into humans.”

With the TRIA valve platform, the company intends to reinvent every aspect of the heart valve – from material to design to manufacturing – by developing surgical and transcatheter valves designed to last a lifetime addressing the historical tradeoffs between tissue and mechanical valves. The TRIA valve platform reimagines the heart valve by combining the company’s proprietary  LifePolymer with an innovative valve design intended to resist calcification, withstand stresses and strains without failure, and restore patient quality of life without requiring lifelong use of anticoagulants.

The company’s TRIA aortic surgical valve has been studied in humans out to two years. One year results for the aortic surgical valve recently published in JACC: Cardiovascular Interventions showed that it met all of its primary endpoints, including valve effective orifice area (EOA) and clinically significant improvement in New York Heart Association (NYHA) class.

“In the process of making a better valve, we will also be changing the face of the heart valve industry. The Company is democratizing the manufacturing of heart valves by eliminating the need for a central large skilled human workforce and replacing it with a small footprint robotic manufacturing pod that can be placed in any region of the world. We are not only solving historical problems with both tissue and mechanical valves, but also making valve manufacturing incredibly efficient and accessible,” said Foldax CEO Frank Maguire.

To learn more about Foldax, visit www.foldax.com

Related content:

Foldax Gets Indian Approval to Start Clinical Trial of Tria Biopolymer Surgical Aortic Valve

Foldax to Initiate FDA Clinical Study of Biopolymer Mitral Heart Valve

Foldax Gets $20 Million to Finance Innovative Heart Valve Technology

 

Related Content

News | Heart Valve Technology

May 19, 2022 — A study of 1-year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV) ...

Home May 19, 2022
Home
News | Heart Valve Technology
May 5, 2022 – Foldax, Inc. has announced that the first patients have been enrolled in the Drugs Controller General of ...
Home May 05, 2022
Home
News | Heart Valve Technology

April 27, 2022 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall for the Medtronic Harmony ...

Home April 27, 2022
Home
News | Heart Valve Technology
March 2, 2022 – An international study led by a researcher from Tel Aviv University offers a novel technology that can ...
Home March 02, 2022
Home
News | Heart Valve Technology
February 14, 2022 — SMT (Sahajanand Medical Technologies Limited) has announced the publication of Hydra Transcatheter ...
Home February 14, 2022
Home
News | Heart Valve Technology

December 13, 2021 - Foldax Inc. announced that the Drugs Controller General of India (DCGI), India’s regulatory body for ...

Home December 13, 2021
Home
News | Heart Valve Technology

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

Home November 09, 2021
Home
Feature | Heart Valve Technology

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...

Home July 08, 2021
Home
News | Heart Valve Technology

June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart ...

Home June 02, 2021
Home
News | Heart Valve Technology

May 4, 2021 – A new study, presented at the 2021 American Association for Thoracic Surgery (AATS) 101st annual meeting ...

Home May 04, 2021
Home
Subscribe Now